Acutaas Chemicals Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹26,369 Cr
- Book Value
- ₹202
- Stock P/E
- 68.3
- Dividend Yield
- 0.05%
- ROE
- 24.1%
- ROCE
- 31.6%
- PEG Ratio
- 1.49
- EV/EBITDA
- 45.9
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Technical snapshot
EOD ·Acutaas Chemicals Ltd closed at ₹3,904.00 on 3 November 2026, up 0.3% on the day, 8.9% above its 50-day average, 18.5% below its 52-week high, with volume at 0.49× its 20-session average.
- RSI 14
- 64.3
- vs 50-day SMA
- +8.9%
- vs 200-day SMA
- +10.7%
- From 52-week high
- -18.5%
- Relative volume
- 0.49×
- 20-day return
- +23.7%
End-of-day prices from exchange-published files (NSE/BSE bhavcopy), updated after market close. Descriptive statistics, not investment advice.
What the exchange files show
NSE EOD ·Acutaas Chemicals Ltd settled 43.9% of its traded volume as delivery on 3 November 2026, against a median of 48.6% across 109 sessions since 29 May 2026, below the 46.1% median for liquid NSE shares that day.
NSE assigns Acutaas Chemicals Ltd a 20% daily price band and closed at neither limit in the 109 sessions it has carried that band here.
Under exchange surveillance. ASM Stage I as of 3 Nov 2026. What a given stage carries varies — the measures range from higher margin to a narrowed price band, trade-for-trade settlement and, at the highest GSM stages, trading in a weekly call auction. The band this page shows is the one the exchange's file records for it today. What ASM and GSM mean →
- Delivery, latest
- 43.9%
- Delivery, 109-session median
- 48.6%
- Delivery range
- 21.2–67.8%
- Daily price band
- 20%
- Close x volume, latest
- ₹170 cr
- Series
- EQ
Corporate actions
- 17 Sept 2026 — Dividend - Rs 2.50 Per Share
Prices, delivery and the price band come from NSE's published end-of-day files (sec_bhavdata_full and sec_list), covering 109 sessions from 29 May 2026. Surveillance status, disclosed deals and corporate actions come from separate NSE feeds on their own schedules and are not bounded by that window. Descriptive exchange data, not investment advice. What delivery percentage does and does not tell you →
Acutaas Chemicals share price today
Acutaas Chemicals (NSE: ACUTAAS — renamed from Ami Organics in 2025) runs two structural stories through one P&L. The base: advanced pharma intermediates for blockbuster molecules, a qualified-supplier business with global generics and innovator clients. The kicker: battery electrolyte additives (VC/FEC chemistry) as India’s cell-manufacturing buildout localises its supply chain. Three-year profit CAGR: 62%, with 37.1% operating margins that scream specialty rather than commodity.
At 68.3× with a PEG of 1.49, the valuation requires both the pharma-intermediates and battery-additives growth curves to deliver with little room for delay.
Two S-curves, one plant network
Pharma intermediates compound on molecule wins: once designed into a drug’s supply chain, revenue persists for the product’s life, and Acutaas keeps adding molecules ahead of patent cliffs. Electrolyte additives are earlier-curve: global supply concentrates in China, every Indian gigafactory needs local qualification, and Acutaas moved first among Indian listings. If even one story delivers fully, today’s earnings base doubles; the multiple prices substantial delivery already.
Watch-items: electrolyte-additive qualification wins (binary, chunky), pharma client concentration, capex execution across sites, and the 32.7% promoter holding — low, a legacy of the founder-dilution path.
The numbers
Financial snapshot — 5 August 2026
| Metric | Value |
|---|---|
| Market cap | ₹26,369 Cr |
| P/E (TTM) | 68.3 |
| EV/EBITDA | 45.9 |
| Operating margin | 37.1% |
| ROE / ROCE | 24.1% / 31.6% |
| Debt to equity | 0.02 |
| Sales CAGR (5y) | 31.5% |
| Profit CAGR (5y) | 45.8% |
| Promoter holding | 32.7% |
| EPS (TTM) | ₹47.23 |
Acutaas Chemicals share price target 2026 to 2030
EPS base ₹47.23 (TTM). Bear: battery story stalls, pharma alone — 12% growth, multiple at 34×. Base: both engines compound — 20% growth at 50×. Bull: electrolyte additives scale with India’s gigafactories — 28% growth at 66×.
From ₹3,224, the base case is ≈ +82% over four and a half years; the bear is −12%. High-multiple dual-story stocks reward two things: entering on doubt and verifying delivery quarterly. The range below handles the first; our monthly reviews handle the second.
Reasons to own Acutaas (at the right price)
- Two structural S-curves — pharma intermediates today, battery chemistry tomorrow.
- 37% operating margins prove specialty pricing power.
- Qualified-supplier stickiness in both businesses once designed in.
- 31.6% ROCE with near-zero debt funds both build-outs from the company’s own balance sheet.
- First-mover among Indian listings in electrolyte-additive localisation.
The risks: 68× needs both stories to keep delivering, battery qualification cycles are slow and binary, and the 32.7% promoter stake offers less anchor than typical.
What to weigh at the current price
At 68.3× earnings, Acutaas is priced for both businesses to deliver; the valuation becomes compelling only when two credible stories cost closer to one.
FAQ
What is the Acutaas Chemicals share price target for 2030? The table above sets out bear, base and bull scenarios for each year through 2030. These are valuation sensitivities, not promised prices.
Why did Ami Organics change its name? The 2025 rebrand to Acutaas reflects the widened portfolio beyond the original pharma-intermediates identity — the businesses and management continue unchanged.
What are electrolyte additives? Specialty molecules (like vinylene carbonate) added to lithium-ion electrolytes to extend battery life. Tiny volumes, high value, dominated by China — exactly the import-substitution profile India’s cell buildout must localise.
When are Acutaas’s next results? Check the results calendar and confirm the announced date in the relevant exchange filing.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.